Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer

Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer

Treatment options for triple negative breast cancer (TNBC) are generally limited to cytotoxic chemotherapy. Recently, anti-epidermal growth factor receptor (EGFR) therapy has been introduced for TNBC patients. We engineered a novel nanobioconjugate based on a poly(β-L-malic acid) (PMLA) nanoplatform...

Full description

Bibliographic Details
Published:
Online Access:	http://hdl.handle.net/2047/d20003210

Similar Items

Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.
by: Satoshi Inoue, et al.
Published: (2012-01-01)

Targeting EGFR in Triple Negative Breast Cancer
by: Naoto T. Ueno, Dongwei Zhang
Published: (2011-01-01)

Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
by: Jason J. Zoeller, et al.
Published: (2020-11-01)

Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer
by: Anusha Sebastian, et al.
Published: (2016-12-01)

The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
by: Meyer, Aaron Samuel, et al.
Published: (2014)

Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
by: Somaira Nowsheen, et al.
Published: (2012-01-01)

Targeting therapy on the EGFR using novel nanodiamond-drug composites in human triple negative breast cancer
by: HO, YU, et al.
Published: (2017)

Regulation of low-density lipoprotein receptor expression in triple negative breast cancer by EGFR-MAPK signaling
by: Tiffany Scully, et al.
Published: (2021-09-01)

Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies
by: Olga Y. Korolkova, et al.
Published: (2020-08-01)

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
by: Alexandra Canonici, et al.
Published: (2020-01-01)

EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo
by: Lin Xia, et al.
Published: (2020-01-01)

Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen.
by: Tadanobu Nagaya, et al.
Published: (2015-01-01)

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer
by: Ting Li, et al.
Published: (2021-07-01)

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
by: Aleksandra Simiczyjew, et al.
Published: (2018-09-01)

Establish and authenticate an animal model for the triple negative breast cancer with high expression of PD-L1 and EGFR
by: Shi-Jian Wang, et al.
Published: (2019-01-01)

Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
by: Abderrahim El Guerrab, et al.
Published: (2011-01-01)

Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling
by: Pradip Shahi Thakuri, et al.
Published: (2020-01-01)

Development of novel bispecific antibody to enhance therapeutic effect of T cells against EGFR-expressing triple negative breast cancer
by: Yi-Ting Lee, et al.
Published: (2019)

Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
by: So-Yeon Park, et al.
Published: (2019-07-01)

Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer
by: Zhen Wang, et al.
Published: (2021-01-01)

EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling
by: Song X, et al.
Published: (2020-01-01)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
by: Nina Radosevic-Robin, et al.
Published: (2021-09-01)

Ultrasound-Mediated Cavitation Enhances EGFR-Targeting PLGA-PEG Nano-Micelle Delivery for Triple-Negative Breast Cancer Treatment
by: Libin Chen, et al.
Published: (2021-07-01)

Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides.
by: Yung-Luen Yu, et al.
Published: (2013-01-01)

Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression
by: Sha Sha, et al.
Published: (2017-09-01)

Androgen Receptor Expression in Triple-Negative Breast Cancer
by: Samane Jam, et al.
Published: (2019-05-01)

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
by: Yingnan Si, et al.
Published: (2021-07-01)

Triple-negative breast cancer: new perspectives for targeted therapies
by: Tomao F, et al.
Published: (2015-01-01)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
by: Chia-Jung Li, et al.
Published: (2021-06-01)

Triple-Negative Breast Cancer
by: Quyen D. Chu, et al.
Published: (2012-01-01)

Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway
by: Jianjun Han, et al.
Published: (2018-06-01)

Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
by: Rajeshwari Mehta, et al.
Published: (2013-01-01)

Effects of Annona muricata Extract on Triple-Negative Breast Cancer Cells Mediated Through EGFR Signaling
by: Alshaeri HK, et al.
Published: (2020-12-01)

SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity
by: Huiquan Liu, et al.
Published: (2019-09-01)

Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis
by: Li Zhang, et al.
Published: (2015-01-01)

MiR-133 Targets YES1 and Inhibits the Growth of Triple-Negative Breast Cancer Cells
by: Guochen Zhang MD, et al.
Published: (2020-05-01)

Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition
by: Elizabeth Garcia, et al.
Published: (2021-06-01)

Predictive Role of EGFR, IGF-1R, VEGFR2 and HIF-1? Expression on Survival of Patients with Triple-negative Breast Cancer
by: Safa Najafi, et al.
Published: (2014-11-01)

A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective Against Triple Negative Breast Cancer Via Multiple Mechanisms of Action
by: Nishant Mohan, et al.
Published: (2021-03-01)

ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression
by: Li K, et al.
Published: (2014-06-01)